P

Phio Pharmaceuticals Corp
D

PHIO

2.46000
USD
0.00
(0.00%)
مغلق
حجم التداول
202
الربح لكل سهم
-16
العائد الربحي
-
P/E
-0
حجم السوق
2,595,839
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    0.01000
    (0.28%)
    3.64000 USD
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    A
    ARCT
    -2.310
    (-12.60%)
    16.020 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    V
    VIR
    -0.63500
    (-7.35%)
    8.01000 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    المزيد
الأخبار

العنوان: Phio Pharmaceuticals Corp

القطاع: Healthcare
الصناعة: Biotechnology
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.